Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement on the USMCA Biotech Corn Dispute…
Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) corn. In response, John Crowley, President…
Learn more
BIO Applauds the Inclusion of Important Health…
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a year-end government funding bill that includes many…
Learn more
BIO Appoints Veteran Communications Leader Sarah…
Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications veteran, will join BIO’s senior leadership team. Her first day will be…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
House passage of bill to restore full R&D expensing a "big step forward" for biomedical innovation
February 1, 2024
Legislation to restore immediate R&D expensing passed the House by 357-70 yesterday. Following the vote, BIO's Chief Advocacy Officer, Nick Shipley, made the following statement:  "The bipartisan legislation passed by the U.S. House…
Bipartisan EPIC Act a "critical step forward" to incentivize small molecule drug innovation
January 31, 2024
Yesterday, Reps. Greg Murphy, M.D. (R-NC), Don Davis (D-NC) and Brett Guthrie introduced the Ensuring Pathways to Innovative Cures (EPIC Act), legislation to fix the “pill penalty.” BIO President and CEO, Rachel King, made the following statement: …
New BIO Report Finds More Innovation & Investment Needed in Vaccine Development
January 25, 2024
Today, the Biotechnology Innovation Organization (BIO) released a new report, "The State of Innovation in Vaccines and Prophylactic Antibodies for Infectious Diseases," examining the latest scientific and investment trends in vaccine development…
BIO and ICBA Release Updated Report on Biotechnology’s Role in Meeting UN Sustainable Development Goals
December 21, 2023
The Biotechnology Innovation Organization (BIO) released an updated report produced in partnership with the International Council of Biotechnology Associations (ICBA) that highlights biotechnology’s role in meeting the United Nations’ 17 Sustainable…
BIO Applauds U.N. FAO on Food and Climate Roadmap
December 14, 2023
The Biotechnology Innovation Organization (BIO) today welcomed the United Nations (U.N.) Food and Agriculture Organization’s announcement of a new roadmap outlining how the world can attain global food security by 2050 without breaching the global…
SCOTUS should preserve FDA's "mandated authority" and "scientific and medical expertise" in new case
December 13, 2023
Today, the Supreme Court announced it will soon weigh in on a case that challenges how the Food and Drug Administration (FDA) regulates mifepristone, a drug it approved almost 25 years ago. BIO interim president and CEO, Rachel King, made the…
New Survey Finds Majority of Americans Support Incentivizing Biotech to Address Climate Change
December 8, 2023
Most Americans Recognize that Biotech Is ‘Climate Tech’ A new poll from the Biotechnology Innovation Organization (BIO) shows that majorities of Americans agree that biotech plays an important role in addressing climate change and federal…
New BIO Poll Reveals Americans Strongly Support the Orphan Cures Act
December 7, 2023
Today, the Biotechnology Innovation Organization released a poll that shows voters overwhelmingly support the ORPHAN Cures Act, a recently introduced bill that would incentivize rare disease drug development.   The…
Using March-In as a Price Control Mechanism Is a “Dangerous Precedent To Set”
December 7, 2023
The White House just announced plans to use Bayh-Dole “march-in rights” to step in and license patent rights of drugs “developed with federal funding” to other manufacturers when the price of the drug is deemed too high. BIO's Chief Advocacy Officer…
Industry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO
December 5, 2023
The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President and CEO, effective March 4. He will replace Rachel King, a longtime BIO board member and…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today